Adial Pharmaceuticals, Inc. (ADIL) vs Satellos Bioscience Inc. (MSLE)

A side-by-side comparison of Adial Pharmaceuticals, Inc. and Satellos Bioscience Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Adial Pharmaceuticals, Inc. logo
ADIL
Adial Pharmaceuticals, Inc.
$11M
$4.23HealthcareDelayed quote: Oct 6, 2026, 12:51 PM EDT
Satellos Bioscience Inc. logo
MSLE
Satellos Bioscience Inc.
$10M
$8.09HealthcareDelayed quote: Oct 6, 2026, 12:51 PM EDT

Total return — ADIL vs MSLE

growth of $100 · dividends reinvested · last 1y
ADIL -24.3% (-24.3%/yr)MSLE +13.7% (+13.7%/yr)MSLE compounded faster over this window
50100150Start $100$76$114
ADIL MSLE

ADIL vs MSLE: by the numbers

  • •ADIL is the larger company ($11M vs $10M market cap).

Metrics side by side

Valuation

MetricADILMSLE
P/B ratioN/A0.17

Profitability

MetricADILMSLE
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-37052.06%-57.34%
ROIC-240.64%-59.35%

Growth (annualized)

MetricADILMSLE
Total return CAGR (5Y)-71.86%N/A

Go deeper

Full ADIL analysisFull MSLE analysisInteractive comparison tool

Dig into the metrics

Adial Pharmaceuticals ROESatellos Bioscience ROEAdial Pharmaceuticals operating marginSatellos Bioscience operating marginAdial Pharmaceuticals revenue growthSatellos Bioscience revenue growthAdial Pharmaceuticals free cash flowSatellos Bioscience free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.